SEC Form 4 · accession 0001193125-26-342487
Attovia Therapeutics, Inc. · ATTO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Aug 6, 2026
Accepted (ET)
Aug 10, 2026 · 4:30 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0002058707
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Aug 6, 2026 | C | 1,957,138 | — | A | 1,957,138 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series C Redeemable Convertible Preferred StockF2,F1 | — | Aug 6, 2026 | C | 18,181,818 | D | — | — | Common Stock | 1,957,138 | — | D |
Explanation of responses
- F1Each share of Series C Redeemable Convertible Preferred Stock ("Series C Preferred Stock") automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering at the applicable conversion ratio of 9.29-for-one. The Series C Preferred Stock had no expiration date.
- F2Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.